Description
A selective antagonist of σ1 receptors (Ki = 0.9 nM in a radioligand binding assay); selective for σ1 receptors with binding affinity values greater than 10,000 nM for human recombinant dopamine, opioid, PCP, and serotonin receptors in vitro; protects against convulsions and lethality induced by cocaine and reduces cocaine-induced locomotor activity; reduces haloperidol- and DTG-induced dystonias in vivo; attenuates mechanical allodynia and microglial activation in a rat model of bone cancer pain,
Formal name: N1-[2-(3,4-dichlorophenyl)ethyl]-N1,N2,N2-trimethyl-1,2-ethanediamine, dihydrobromide
Synonyms:
Molecular weight: 437
CAS: 138356-21-5
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience|Behavioral Neuroscience|Addiction Research||Research Area|Neuroscience|Pain Research||Research Area|Neuroscience|Seizure Disorders